

Neuromuscular Disorders (NMD) Panel Sequence Analysis and Exon-Level Deletion/Duplication* Testing of 99 Genes

Panel Gene List: ACTA1, ANO5, ASAH1, ATP2A1, B3GALNT2, B4GAT1*, BAG3, BICD2, BIN1, BVES, CACNA1S, CAPN3, CAV3, CCDC78, CFL2, CHKB, CLCN1, CNTN1, COL6A1, COL6A2, COL6A3, COL12A1, CRYAB, DAG1, DES, DMD, DNAJB2, DNAJB6, DNM2, DOK7, DPM1, DPM2, DPM3, DYNC1H1, DYSF, EGR2, EMD**, FHL1, FKRP, FKTN*, FLNC, GAA, GBE1, GMPPB, GNE, IGHMBP2, ISPD, ITGA7, KBTBD13, KLHL40, KLHL41, LAMA2, LAMP2, LARGE, LDB3, LMNA, LMOD3, MEGF10, MICU1, MTM1, MYH2, MYH7, MYOT, NEB, PHKA1, PLEC, PLEKHG5, POMGNT1**, POMK, POMT1, POMT2, PYGM, RYR1, SCN4A, SEPN1, SGCA, SGCB, SGCD, SGCG, SIL1, SLC52A2, SLC52A3, SYNE1, TCAP, TMEM5, TNNI2**, TNNT1**, TNPO3, TOR1AIP1, TPM2, TPM3, TRAPPC11, TRIM32, TRIP4, TRPV4, TTN, UBA1, VCP, VRK1

* Sequence analysis only of B4GAT1 and FKRP genes.

** Only whole gene deletions or duplications may be detected for EMD, POMGNT1, TNNI2, TNNT1 genes.

Clinical Features:

Disorders of the neuromuscular system are clinically and genetically heterogeneous, but generally impair the function of the musculoskeletal or peripheral nervous systems, leading to progressive muscle weakness. Neuromuscular disorders (NMDs) are classified into distinct clinical categories, and the diagnosis is based on clinical presentation, genetic testing, electromyography (EMG), muscle biopsy histopathology, biochemical testing and other ancillary testing.¹ The age-of-onset of clinical symptoms depends on the specific disease and can range from the neonatal period to adulthood. Most NMDs have a genetic cause, although some NMDs are acquired or pharmaceutical-induced.² The prevalence of the hereditary neuromuscular disorders has been reported to be 1 in 3,500.³

Genes on this panel cause muscular dystrophies, myopathies, spinal muscular atrophies, and myotonias. The muscular dystrophies are caused by the destruction of muscle fibers, leading to progressive muscle weakness and wasting. The clinical features are variable depending on the specific diagnosis but often include elevated creatine kinase (CPK) levels, cardiomyopathy, joint contractures, respiratory complications, developmental delay, and rarely brain and eye abnormalities. Examples of muscular dystrophies with a known genetic etiology include Duchenne and Becker muscular dystrophy, Emery-Dreifuss muscular dystrophy, limb-girdle muscular dystrophy, congenital muscular dystrophy, and Myofibrillar myopathy.^{4,5,6} The congenital myopathies are characterized by a reduced ability of the muscles to contract, resulting in muscle weakness and decreased muscle tone with onset in early childhood. Examples of myopathies include nemaline myopathy, central core disease, multiminicore

disease, and centronuclear myopathy.^{7,8} Spinal muscular atrophies are characterized by the degeneration of the antenatal anterior horn cells, leading to progressive muscle weakness and wasting often associated with respiratory problems. The nondystrophic myotonias are caused by functional defects in chloride or sodium channels and are often referred to as channelopathies. Examples include paramyotonia congenita and hypokalemic periodic paralysis, which manifest as attacks of transient weakness and reversible flaccid paralysis and result in muscle stiffness, fatigue, and pain.^{9,10} Individuals with channelopathies and some other forms of NMDs are at increased risk for intraoperative complications such as malignant hyperthermia, rhabdomyolysis, and hyperkalemia when exposed to anesthetics commonly used during surgery.^{11,12} The NMD Panel can assist in the diagnosis of neuromuscular disorders without requiring invasive diagnostic testing such as muscle biopsy. Confirmation of a clinical diagnosis allows for development of a comprehensive medical management plan, including monitoring for cardiac and respiratory complications.

Genetics:

The neuromuscular disorders included on this panel are inherited in either an autosomal dominant, autosomal recessive, or X-linked manner or they may be the result of a *de novo* variant.

Test Methods:

Using genomic DNA from the submitted specimen, the complete coding regions and splice site junctions of the genes on this panel are enriched using a proprietary targeted capture system developed by GeneDx for next-generation sequencing with CNV calling (NGS-CNV). For FKTN, nucleotides surrounding the insertion site of an ALU-based founder mutation in the 3' UTR are also captured to determine if the insertion is present or absent. Presence of an insertion is confirmed using multiplex PCR, followed by gel electrophoresis. The enriched targets are simultaneously sequenced with paired-end reads on an Illumina platform. Bi-directional sequence reads are assembled and aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19. After gene specific filtering, data are analyzed to identify sequence variants and most deletions and duplications involving coding exons. Alternative sequencing or copy number detection methods are used to analyze regions with inadequate sequence or copy number data. Reportable variants include pathogenic variants, likely pathogenic variants and variants of uncertain significance. Likely benign and benign variants, if present, are not routinely reported but are available upon request.

The technical sensitivity of sequencing is estimated to be > 99% at detecting single nucleotide events. It will not reliably detect deletions greater than 20 base pairs, insertions or rearrangements greater than 10 base pairs, or low-level mosaicism. The copy number assessment methods used with this test cannot reliably detect copy number variants of less

than 500 base pairs or mosaicism and cannot identify balanced chromosome aberrations. Assessment of exon-level copy number events is dependent on the inherent sequence properties of the targeted regions, including shared homology and exon size. Gene specific exclusions for exon-level deletion/duplication testing for this panel are: B4GAT1 and FKRP genes, no copy number testing; EMD, POMGNT1, TNNI2, and TNNT1 genes, only whole gene deletions or duplications may be detected. Missense variants in regions of high homology in the TTN gene may not be reliably identified due to inherent properties of the DNA.

References:

1. Lisi & Cohn (2011) Dev Med Child Neurol (7): 586-599.
2. Laing (2012) Critical Rev in Clinical Lab Sci 49(2):33-48
3. Emery (2002) Lancet 359:687-95.
4. Bonne et al. Emery-Dreifuss Muscular Dystrophy. 2004 Sep 29 [Updated 2013 Jan 17]. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1436/>
5. Darras & Urion. Dystrophinopathies. 2000 Sep 5 [Updated 2011 Nov 23]. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1119/>
6. Pegoraro & Hoffman. Limb-Girdle Muscular Dystrophy Overview. 2000 Jun 8 [Updated 2012 Aug 30]. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1408/>
7. Selcen & Engel. Myofibrillar myopathy. 2005 Jan 28 [Updated 2012 Oct 29]. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1499/>
8. Sparks et al. Congenital Muscular Dystrophy Overview. 2001 Jan 22 [Updated 2012 Aug 23]. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1291/>
9. Matthews et al., (2010) Brain 133:9-22.
10. Sternberg et al. Hypokalemic Periodic Paralysis. 2002 Apr 30 [Updated 2009 Apr 28]. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1338/>
11. Klingler et al., (2005) Neuromuscul Disord 15:195-206.
12. Rosenberg et al., (Malignant hyperthermia sensitivity 2003 [Updated 2013] GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1146/>

Neuromuscular Disorders Panel - 99 Genes

Gene	Inheritance	Disease Associations	Diagnostic Yield in Selected Population(s)
ACTA1	AD	Congenital fiber-type disproportion myopathy /Nemaline myopathy (NM)	15-25% of NM is attributed to mutations in ACTA1 ¹
ANO5	AR	Limb-girdle muscular dystrophy (LGMD) type 2L; Miyoshi MD	Founder mutation in the Northern European populations ^{2,3}
ASAH1	AR	Spinal Muscular Atrophy	Rare ¹²⁴
ATP2A1	AR	Brody myopathy	Common in Brody myopathy ⁴
B4GAT1* (B3GNT1)	AR	Walker-Warburg syndrome	Rare ⁹⁷
B3GALNT2	AR	Walker-Warburg syndrome; Muscle-eye-brain disease (MEB)	Rare ⁵
BAG3	AD	Myofibrillar myopathy ⁶	~5% of MFM is attributed to mutations in BAG3 ^{6,7}
BICD2	AD	Autosomal dominant congenital spinal muscular atrophy (DCSMA)	Rare ^{98,99}
BIN1	AR	Centronuclear myopathy	Rare ⁸
BVES	AR	Limb-Girdle Muscular Dystrophy 2X	Unknown ¹⁰²
CACNA1S	AD/AR	Hypokalemic periodic paralysis type 1	~60% of patients with hypokalemic periodic paralysis type 1 ⁹

<i>CAPN3</i>	AR	LGMD type 2A	~30% of LGMD in the United States. Founder mutations in the Amish, La Reunion Island, Basque (Spain) & Turkish populations ^{10, 11}
<i>CAV3</i>	AD	LGMD type 1C	~3% of LGMD in the United States ¹¹
<i>CCDC78</i>	AD	Centronuclear Myopathy	Rare ¹⁰³
<i>CFL2</i>	AR	Nemaline myopathy	Rare ^{1, 12}
<i>CHKB</i>	AR	Mitochondrial CMD (congenital megaconial type muscular dystrophy)	Rare ¹³
<i>CLCN1</i>	AD/AR	Myotonia congenita	~95% of patients with myotonia congenita ⁹
<i>CNTN1</i>	AR	Compton-North congenital myopathy	Rare ¹⁴
<i>COL6A1</i>	AD/AR	Ullrich CMD/Bethlem myopathy	~62% of patients with Ullrich or Bethlem myopathy have a mutation in one of the three collagen VI genes (<i>COL6A1</i> , <i>COL6A2</i> , <i>COL6A3</i>) ¹⁵
<i>COL6A2</i>	AD/AR	Ullrich CMD/Bethlem myopathy	~62% of patients with Ullrich or Bethlem myopathy have a mutation in one of the three collagen VI genes (<i>COL6A1</i> , <i>COL6A2</i> , <i>COL6A3</i>) ¹⁵
<i>COL6A3</i>	AD/AR	Ullrich CMD/Bethlem myopathy	~62% of patients with Ullrich or Bethlem myopathy have a mutation in one of the three collagen VI genes (<i>COL6A1</i> , <i>COL6A2</i> , <i>COL6A3</i>) ¹⁵
<i>COL12A1</i>	AD/AR	Ullrich CMD/Bethlem myopathy	Rare ¹⁰⁴
<i>CRYAB</i>	AD/AR	Myofibrillar myopathy 2	~3% of MFM ⁷
<i>DAG1</i>	AR	Primary dystroglycanopathy, LGMD with early onset and intellectual disability	Rare ³⁷
<i>DES</i>	AD/AR	LGMD type 1D/Myofibrillar myopathy ¹	~7% of MFM Rare in LGMD ^{7, 17}
<i>DMD</i>	X-linked	Duchenne / Becker muscular dystrophy (DMD/BMD)	25-30% of mutations are caused by single point mutations or small rearrangements, the majority of which are detectable by this test. 65-70% of disease causing mutations in <i>DMD</i> are deletions/duplications. ¹⁸⁻²⁰
<i>DNAJB2</i>	AR	Spinal muscular atrophy	Rare ¹²⁵
<i>DNAJB6</i>	AD	LGMD type 1E, DNAJB6-related myofibrillar myopathy	Rare ²¹
<i>DNM2</i>	AD	Centronuclear myopathy	Rare ^{8, 22}
<i>DOK7</i>	AR	Congenital myasthenia syndrome, with LGMD presentation	10-21% of Congenital Myasthenia syndrome, Founder mutation in European, Canadian, and Brazilian populations ^{105,106,107,108,109}
<i>DPM1</i>	AR	Congenital disorder of glycosylation type 1e	Rare ²³
<i>DPM2</i>	AR	CMD with intellectual disability and severe epilepsy	Rare ²⁴
<i>DPM3</i>	AR	CMD with intellectual disability and severe epilepsy	Rare ²³
<i>DYNC1H1</i>	AD	Spinal muscular atrophy lower extremity	Rare ²⁵⁻²⁷
<i>DYSF</i>	AR	LGMD type 2B	~19% of LGMD in the United States ^{10, 28, 29}
<i>EGR2</i>	AD/AR	Charcot-Marie-Tooth	<2% of patients with CMT1 ¹¹⁰
<i>EMD**</i>	X-linked	Emery-Dreifuss muscular dystrophy (EDMD)- X-linked	~61% of patients with XL-EDMD ^{10, 30}
<i>FHL1</i>	X-linked	X-linked myopathy with reducing bodies; Emery-Dreifuss muscular dystrophy; scapuloperoneal myopathy	~10% of patients with XL-EDMD ^{31, 32} Rare in scapuloperoneal myopathy
<i>FKRP*</i>	AR	Walker-Warburg syndrome; CMD with/without intellectual disability and microcephaly; LGMD type 2	~6% of LGMD ¹¹ ~9% of the alpha-dystroglycanopathies ^{10, 33}
<i>FKTN</i>	AR	Fukuyama congenital muscular dystrophy; LGMD type 2M	~7% of the alpha-dystroglycanopathies Includes the Japanese founder mutation in the 3' UTR and an intronic point mutation found in the Korean population ³⁴⁻³⁷ Rare cause of LGMD

<i>FLNC</i>	AD	Myofibrillar myopathy 5	~3% of MFM is attributed to mutations in <i>FLNC</i> ⁷
<i>GAA</i>	AR	Pompe disease (Glycogen storage disease type II)	c.-32-13 T>G has been reported in up to 42% of alleles in the adult onset form (detectable by this test); a large deletion of exon 18 is common in some European populations ^{38, 39}
<i>GBE1</i>	AR	Glycogen Storage Disease IV	3% of glycogen storage disease ¹¹¹
<i>GMPPB</i>	AR	Muscular dystrophy-dystroglycanopathy (LGMD), type C; Walker-Warburg syndrome	Rare ⁴⁰
<i>GNE</i>	AR	<i>GNE</i> myopathy, hereditary inclusion body myopathy	70-80% of individuals diagnosed with hereditary inclusion body myopathy or another <i>GNE</i> related myopathy ^{41, 42} Common mutation in Middle Eastern Jewish population
<i>IGHMBP2</i>	AR	Spinal muscular atrophy with respiratory distress 1 (SMARD)	~33% of patients with SMARD ⁴³
<i>ISPD</i>	AR	Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies type A7	~30% of Walker-Warburg syndrome and ~11% of alpha-dystroglycanopathies ^{35, 44, 45} Rare in LGMD
<i>ITGA7</i>	AR	Integrin alpha 7-related CMD	Rare ^{46, 47}
<i>KBTBD13</i>	AD	Nemaline myopathy	Unknown ^{48, 49}
<i>KLHL40</i>	AR	Nemaline myopathy	~20% of severe NM ⁵⁰
<i>KLHL41</i>	AR	Nemaline myopathy	Rare ¹¹²
<i>LAMA2</i>	AR	Congenital merosin deficient muscular dystrophy (MDC1A)	~30-50% of patients with congenital muscular dystrophy in the European population have MDC1A ⁵¹⁻⁵³
<i>LAMP2</i>	XL	Danon disease	Rare ⁵⁴
<i>LARGE</i>	AR	Walker-Warburg syndrome; MEB disease	~3% of the alpha-dystroglycanopathies ^{37, 55}
<i>LDB3</i>	AD	Myofibrillar myopathy 4	~11% of MFM ⁷
<i>LMNA</i>	AD/AR	Emery-Dreifuss muscular dystrophy, type 2 (AD); LGMD type 1B; congenital laminopathy (AR)	~45% of patients with AD-EDMD ~12% of LGMD in United States Rare in congenital muscular dystrophies ^{10, 30, 56-58}
<i>LMOD3</i>	AR	Nemaline Myopathy	Rare ¹¹³
<i>MEGF10</i>	AR	Early onset myopathy areflexia, respiratory distress, dysphagia	Rare ⁵⁹⁻⁶¹
<i>MICU1</i>	AR	Myopathy with extrapyramidal signs	Rare ¹¹⁴
<i>MTM1</i>	XL	Centronuclear/Myotubular myopathy	Rare ^{62, 63}
<i>MYH2</i>	AD/AR	Inclusion body myopathy	Rare ¹¹⁵
<i>MYH7</i>	AD/AR	Laing early-onset distal myopathy; Scapuloperoneal myopathy	~95% of individuals with Laing distal myopathy ⁶⁴
<i>MYOT</i>	AD	LGMD type 1A; Myofibrillar myopathy 3	~26% of patients with LGMD ~9% of MFM ^{7, 65}
<i>NEB</i>	AR	Nemaline myopathy	~50% of patients with NM have mutations in this gene; Ashkenazi Jewish founder mutation (deletion containing exon 55) ⁶⁶
<i>PHKA1</i>	XL	Glycogen storage disease type IX (GSD IX)	Rare ¹⁰⁰
<i>PLEC</i>	AR	LGMD type 2Q; epidermolysis bullosa simplex with muscular dystrophy	Rare overall; founder mutation in the Turkish population ^{3, 35}
<i>PLEKHG5</i>	AR	Distal spinal muscular atrophy (aka: distal hereditary motor neuropathies-dHMN)	Rare ⁶⁷
<i>POMGNT1**</i>	AR	Walker-Warburg syndrome; MEB disease	11-18% of the alpha-dystroglycanopathies ^{37, 68, 69}
<i>POMK</i>	AR	Walker-Warburg syndrome; Muscular dystrophy-dystroglycanopathy A12; LGMD C12	Rare ¹¹⁶
<i>POMT1</i>	AR	Walker-Warburg syndrome; CMD with intellectual disability and microcephaly; LGMD type 2K	9-21% of the alpha-dystroglycanopathies ^{37, 68}

POMT2	AR	Walker-Warburg syndrome; CMD with intellectual disability and microcephaly; LGMD type 2N	9-11% of the alpha-dystroglycanopathies ^{37, 70}
PYGM	AR	McArdle disease / glycogen storage disease type V	Rare ¹⁰¹ .
RYR1	AD/AR	Central core disease; Minicore myopathy with external ophthalmoplegia	~89% of central core disease ⁷¹⁻⁷³
SCN4A	AD	Paramyotonia congenital; hyperkalemic periodic paralysis; hypokalemic periodic paralysis type 2	~20% of patients with hypokalemic periodic paralysis ^{9, 74}
SEPN1	AR	CMD with spinal rigidity (RSMD1); Minicore/multicore disease	30-50% of patients with minicore/multicore disease ^{75, 76}
SGCA	AR	LGMD type 2D	~9% of LGMD in the United States ^{10, 77}
SGCB	AR	LGMD type 2E	~5% of LGMD in the United States ¹⁰
SGCD	AR	LGMD type 2F	~1% of LGMD in the United States ¹⁰
SGCG	AR	LGMD type 2C	~3% of LGMD in the United States; founder mutation in the North African and gypsy populations ^{10, 35}
SIL1	AR	Marinesco-Sjogren syndrome	Rare ⁷⁸
SLC52A2	AR	Riboflavin transporter deficiency neuropathy	Rare, 30% of Riboflavin transporter deficiency neuropathy cases ^{117, 118}
SLC52A3	AR	Riboflavin transporter deficiency neuropathy	Rare, 70% of Riboflavin transporter deficiency neuropathy cases ¹¹⁸
SYNE1	AD/AR	Emery-Dreifuss muscular dystrophy, type 4	Rare ⁷⁹
TCAP	AR	LGMD type 2G	Rare overall; founder mutation in the Italian population ^{35, 58}
TMEM5	AR	Walker-Warburg syndrome; MEB disease	Rare ⁸⁰
TTN	AR	LGMD type 2J; Early onset myopathy with fatal cardiomyopathy	Rare overall; founder mutation in the Finnish population ³⁵
TNNI2**	AD	Myopathy and distal arthrogryposis (DA) type 2B	~6% of patients with DA1 ~11% of patients with DA2B ^{81, 82}
TNNT1**	AR	Nemaline myopathy	Rare overall; founder mutation in the Old Order Amish population ^{83, 84}
TNPO3	AD	LGMD 1F	Rare ^{85, 86}
TOR1AIP1	AR	LGMD 2Y	Rare ^{119, 120}
TPM2	AD	Nemaline myopathy	<1% of NM ⁸⁷
TPM3	AD/AR	Nemaline myopathy	2-3% of NM ^{87, 88}
TRAPPC11	AR	LGMD 2S	Rare ¹²¹
TRIM32	AR	LGMD type 2H	Rare overall; founder mutation in Manitoba Hutterites ^{11, 89}
TRIP4	AR	Spinal Muscular Atrophy	Unknown ¹²²
TRPV4	AD	Scapuloperoneal spinal muscular atrophy	Rare ⁹⁰⁻⁹⁴
UBA1	X-linked	X-linked SMA with arthrogryposis and congenital contractures; Spinal muscular atrophy- X-linked 2	Rare ⁹⁵
VCP	AD	Inclusion body myopathy	Unknown ¹²³
VRK1	AR	Spinal muscular atrophy with pontocerebellar hypoplasia; pontocerebellar hypoplasia type 1 (Norman disease)	Rare overall; founder mutation in the Ashkenazi Jewish ⁹⁶

***Sequence analysis only (no deletion/duplication testing) for the B4GAT1 and FKRP genes.**

**** Only whole gene deletions or duplications may be detected for EMD, POMGNT1, TNNI2, and TNNT1 genes.**

References: 1. North KN, Ryan MM. Nemaline Myopathy. 2002 Jun 19 [Updated 2015 Jun 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1288/>. 2. Van der Kooi, A.J., et al. (2013). Neuromuscular Disord. 23, 456-460. 3. Mitsunashi, S., Kang, P.B. (2012). Semin. Pediatr. Neurol. 19, 211-218. 4. Voermans, N.C., et al. (2012). Neuromuscular Disord. 22, 944-954. 5. Stevens, E., et al. (2013) Am. J. Hum. Genet. 92: 354-365, 2013. (PubMed: 23453667) 6. Hayashi, Y.K. (2011). Brain Nerve 63, 1179-1188. 7. Olivé, M., et al. (2013). Curr. Opin. Neurol. 26, 527-535. 8. Böhm et al. (2010) Case report of intrafamilial variability in autosomal recessive centronuclear myopathy associated to a novel BIN1 stop mutation. Orphanet Journal of Rare Diseases 5:35 (PMID: 21129173) 9. Statland, J.M., Barohn, R.J. (2013). CONTINUUM Lifelong Learn. Neurol. 19, 1598-1614. 10. Wicklund, M.P. (2013). Continuum (Minneapolis Minn) 19, 1535-1570. 11. Pegoraro E, H.E. (2012 Aug 30). Limb-Girdle Muscular Dystrophy Overview - GeneReviews® - NCBI Bookshelf, <http://www.ncbi.nlm.nih.gov/books/NBK1408/>. 12. Ockeloen, C.W., et al. (2012). Neuromuscular Disord. 22, 632-639. 13. Mitsunashi, S., Nishino, I. (2013). Curr. Opin. Neurol. 26, 536-543. 14. Compton, A.G., et al. (2008). Am. J. Hum. Genet. 83, 714-724. 15. Butterfield, R.J., et al. (2013). Hum. Mutat. 34, 1558-1567. 16. Dinçer, P., et al. (2003). Neuromuscular Disord. 13, 771-778. 17. Greenberg, S.A., et al. (2012). Ann. Neurol. 71, 141-145. 18. Darras, B.T., Miller, D.T., Urion, D.K. (2011 Nov 23). Dystrophinopathies - GeneReviews® - NCBI Bookshelf, <http://www.ncbi.nlm.nih.gov/books/NBK1119/>. 19. Sarkozy, A., Bushby, K., Mercuri, E. (2013). Emery and Rimoin's Principles and Practice of Medical Genetics, 1-58. 20. Shieh, P.B. (2013). MNeurol. Clin. 31, 1009-1029. 21. Harms, M.B., et al. (2012). Ann. Neurol. 71, 407-416. 22.

Echaniz-Laguna, A., et al. (2013). *Rev. Neurol.* 169, 625-631. 23 . Yang, A.C., et al. (2013). *Mol. Genet. Metab.* 110, 345-351. 24 . Barone, R., et al. (2012). *Ann. Neurol.* 72, 550-558. 25 . Tsurusaki, Y., et al. (2012). *A Neurogenetics* 13, 327-332. 26 . Harms, M.B., et al. (2012). *Neurology* 78, 1714-1720. 27 . Poirier, K., et al. (2013). *Nat. Genet.* 45, 639-647. 28 . Aoki, M. (2010 Apr 22). *Dysferlinopathy - GeneReviews® - NCBI Bookshelf*, <http://www.ncbi.nlm.nih.gov/books/NBK1303/>. 29 . Blandin, G., et al. (2012). *Hum. Mutat.* 33, E2317-E2331. 30 . Bonne, G., Leturcq, F., Ben Yaou, R. (2013 Jan 17). *Emery-Dreifuss Muscular Dystrophy - GeneReviews® - NCBI Bookshelf*, <http://www.ncbi.nlm.nih.gov/books/NBK1436/>. 31 . Schreckenbach, T., et al. (2013). *Muscle Nerve* 47, 127-134. 32 . Schessl, J., et al. (2011). *Semin. Pediatr. Neurol.* 18, 257-263. 33 . Clement, E.M., et al. (2012). *Neuromuscular Disord.* 22, 522-527. 34 . Saito, K. (2012 May 10). *Fukuyama Congenital Muscular Dystrophy*. in: Pagon RA, Adam MP, Ardinger HH, et Al., Editors. *GeneReviews® [Internet]*. Seattle (WA): University of Washington, Seattle; 1993-2014. <http://www.ncbi.nlm.nih.gov/books/NBK1206/>. 35 . Pegoraro, E., Hoffman, E.P. (2012 Aug 30). *Limb-Girdle Muscular Dystrophy Overview - GeneReviews® - NCBI Bookshelf*, <http://www.ncbi.nlm.nih.gov/books/NBK1408/>. 36 . Chang, W., et al. (2009). *Prenat. Diagn.* 29, 560-569. 37 . Godfrey, C., et al. (2011). *Curr. Opin. Genet. Dev.* 21, 278-285. 38 . Hermans, M.M.P., et al. (2004). *Hum. Mutat.* 23, 47-56. 39 . Montalvo, A.L.E., et al. (2006). *Hum. Mutat.* 27, 999-1006. 40 . Carss, K.J., et al. (2013) *Am. J. Hum. Genet.* 93: 29-41, 2013. (PubMed: 23768512) 41 . O'Ferrall, E.K., Sinnreich, M. (2013 Mar 7). *GNE-Related Myopathy - GeneReviews® - NCBI Bookshelf*, <http://www.ncbi.nlm.nih.gov/books/NBK1262/>. 42 . Chaouch, A., et al. (2014). [J Neurol Neurosurg Psychiatry](https://doi.org/10.1136/jnnp-2013-306314). doi: 10.1136/jnnp-2013-306314. [Epub ahead of print] T.J. *Neurol. Neurosurg. Psychiatry.* 43 . Guenther, U., et al. (2007). *Hum. Mutat.* 28, 808-815. 44 . Czeschik, J.C., et al. (2013). *Eur. J. Med. Genet.* 56, 689-694. 45 . Cirak, S., et al. (2013). *Brain* 136, 269-281. 46 . Mayer et al. (1997) Absence of integrin alpha 7 causes a novel form of muscular dystrophy. *Nature Genetics* 17 (3):318-23 (PMID: 9354797) 47 . Valencia, C.A., et al. (2013). *PLoS ONE* 8. 48 . Romero, N.B., Sandaradura, S.A., Clarke, N.F. (2013). *Curr. Opin. Neurol.* 26, 519-526. 49 . Romero, N.B., Clarke, N.F. (2013). *Handb. Clin. Neurol.* 113, 1321-1336. 50 . Ravenscroft, G., et al. (2013). *Am. J. Hum. Genet.* 93, 6-18. 51 . Quijano-Roy, S., Sparks, S., Rutkowski, A. (2012 Jun 7). *LAMA2-Related Muscular Dystrophy - GeneReviews® - NCBI Bookshelf*, <http://www.ncbi.nlm.nih.gov/books/NBK97333/>. 52 . Di Blasi, C., et al. (2005). *Arch. Neurol.* 62, 1582-1586. 53 . Sarkozy, A., Bushby, K., Mercuri, E. (2013). *Muscular Dystrophies. Emery and Rimoin's Principles and Practice of Medical Genetics, 1-58.* 54 . Nishino, et al. (2000) Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). *Nature* 406 (6798):906-10 (PMID: 10972294) 55 . van Reeuwijk, J., et al. (2007). *Hum. Genet.* 121, 685-690. 56 . Clement, E.M., et al. (2012). *Neuromuscular Disord.* 22, 522-527. 57 . Quijano-Roy, S., et al. (2008). *Ann. Neurol.* 64, 177-186. 58 . Sarkozy, A., Bushby, K., Mercuri, E. (2013). *Emery and Rimoin's Principles and Practice of Medical Genetics, 1-58.* 59 . Mitsuhashi, S., et al. (2013). *FEBS Lett.* 587, 2952-2957. 60 . Boyden, S.E., et al. (2012). *Neurogenetics* 13, 115-124. 61 . Mitsuhashi, S., Kang, P.B. (2012). *Semin. Pediatr. Neurol.* 19, 211-218. 62 . Das S, Dowling J, Pierson CR. *X-Linked Centronuclear Myopathy*. 2002 Feb 25 [Updated 2011 Oct 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews® [Internet]*. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1432/>. 63 . Jungbluth, H., Wallgren-Petersson, C. (2013). *Emery and Rimoin's Principles and Practice of Medical Genetics, 1-51.* 64 . Lamont, P., Wallefeld, W., Laing, N.G. (2010 Jun 17). *Laing Distal Myopathy - GeneReviews® - NCBI Bookshelf*, <http://www.ncbi.nlm.nih.gov/books/NBK1433/>. 65 . Hayashi, Y.K. (2011). *Brain Nerve* 63, 1179-1188. 66 . North, K.N., et al. (2014). *Neuromuscular Disord.* 24, 97-116. 67 . Rossor, A.M., et al. (2012). *J. Neurol. Neurosurg. Psychiatry* 83, 6-14. 68 . Mercuri, E., et al. (2009). *Neurology* 72, 1802-1809. 69 . Deisen et al., *J Med Genet* 2004 41: e115 70 . Biancheri, R., et al. (2007). *Biochem. Biophys. Res. Commun.* 363, 1033-1037. 71 . Brislin, R.P., Theroux, M.C. (2013). *Paediatr. Anaesth.* 23, 834-841. 72 . Wu, S., et al. (2006). *Brain* 129, 1470-1480. 73 . Malicdan, M.C.V., Nishino, I. (2010 May 11). *Central Core Disease - GeneReviews® - NCBI Bookshelf*, <http://www.ncbi.nlm.nih.gov/books/NBK1391/>. 74 . Rossignol, E., et al. (2007). *Neurology* 69, 1937-1941. 75 . Sparks SE, Quijano-Roy S, Harper A, et al. *Congenital Muscular Dystrophy Overview*. 2001 Jan 22 [Updated 2012 Aug 23]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews® [Internet]*. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1291/>. 76 . Brislin, R.P., Theroux, M.C. (2013). *Paediatr. Anaesth.* 23, 834-841. 77 . Tétreault, M., et al. (2011). *Can. J. Neurol. Sci.* 38, 747-752. 78 . Anttonen et al. (2005) The gene disrupted in Marinesco-Sjögren syndrome encodes SIL1, an HSPA5 cochaperone. *Nature Genetics* 37 (12):1309-11 (PMID: 16282978) 79 . Attali, R., et al. (2009). *Hum. Mol. Genet.* 18, 3462-3469. 80 . Vuillaumier-Barrot, S., et al. (2012) *Am. J. Hum. Genet.* 91: 1135-1143, 2012. (PubMed: 23217329) 81 . Beck, A.E., et al. (2013). *Am. J. Med. Genet. Part A* 161, 550-555. 82 . Kimber, E., et al. (2012). *Acta Paediatr. Int. J. Paediatr.* 101, 877-887. 83 . Johnston, J.J., et al. (2000). *Am. J. Hum. Genet.* 67, 814-821. 84 . Wallgren-Petersson, C., et al. (2011). *Semin. Pediatr. Neurol.* 18, 230-238. 85 . Melià, M.J., et al. (2013). *Brain* 136, 1508-1517. 86 . Torella, A., et al. (2013). *PLoS ONE* 8. 87 . Romero, N.B., Sandaradura, S.A., Clarke, N.F. (2013). *Curr. Opin. Neurol.* 26, 519-526. 88 . Durling, H.J., et al. (2002). *Neuromuscular Disord.* 12, 947-951. 89 . Mitsuhashi, S., Kang, P.B. (2012). *Semin. Pediatr. Neurol.* 19, 211-218. 90 . Cho, T., et al. (2012). *Tam. J. Med. Genet. Part A* 158 A, 795-802. 91 . Fawcett, K.A., et al. (2012). *J. Neurol. Neurosurg. Psychiatry* 83, 1204-1209. 92 . Nilius, B., Voets, T. (2013). *EMBO Rep.* 14, 152-163. 93 . Zimon, M., et al. (2010). *Brain* 133, 1798-1809. 94 . Deng, H., et al. (2010). *Nat. Genet.* 42, 165-169. 95 . Ramser, J., et al. (2008). *Am. J. Hum. Genet.* 82, 188-193. 96 . Renbaum, P., et al. (2009). *Am. J. Hum. Genet.* 85, 281-289. 97 . Buysse et al. (2013) *Human Molecular Genetics* 22 (9):1746-54 (PMID: 23359570). 98. Synofzik et al. (2014) *J. Neurol. Neurosurg. Psychiatr.* 85 (5):590-2 (PMID: 24336790). 99. Peeters et al. (2013) *American Journal Of Human Genetics* 92 (6):955-64 (PMID: 23664119). 100. Ørngreen et al. (2008) *Neurology* 70 (20):1876-82 (PMID: 18401027). 101. De et al. (2015) *Genet.Med.* : (PMID: 25741863). 102. Schindler et al. (2016) *J. Clin. Invest.* 126 (1):239-53 (PMID: 26642364) 103. Majczenko et al. (2012) *American Journal Of Human Genetics* 91 (2):365-71 (PMID: 22818856) 104. Zou et al. (2014) *Hum. Mol. Genet.* 23 (9):2339-52 (PMID: 24334604) 105. Engel et al. (2012) *Neuromuscul. Disord.* 22 (2):99-111 (PMID: 22104196) 106. Finlayson et al. (2013) *Pract Neurol* 13 (2):80-91 (PMID: 23468559) 107. Abicht et al. (2012) *Human Mutation* 33 (10):1474-84 (PMID: 22678866) 108. Beeson et al. (2006) *Science (New York, N.Y.)* 313 (5795):1975-8 (PMID: 16917026) 109. Srour et al. (2010) *Neuromuscul. Disord.* 20 (7):453-7 (PMID: 20610155) 110. Bird TD. *Charcot-Marie-Tooth Neuropathy Type 1*. 1998 Aug 31 [Updated 2015 Mar 26]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews® [Internet]*. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1205/>. 111. Magoulas PL, El-Hattab AW. *Glycogen Storage Disease Type IV*. 2013 Jan 3. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews® [Internet]*. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK115333/>. 112. Gupta et al. (2013) *American Journal Of Human Genetics* 93 (6):1108-17 (PMID: 24268659) 113. Yuen et al. (2014) *J. Clin. Invest.* 124 (11):4693-708 (PMID: 25250574) 114. Logan et al. (2014) *Nature Genetics* 46 (2):188-93 (PMID: 24336167) 115. Tajsharghi et al. (2010) *Brain* 133 (Pt 5):1451-9 (PMID: 20418530) 116. Di et al. (2014) *Human Molecular Genetics* 23 (21):5781-92 (PMID: 24925318) 117. Foley et al. (2014) *Brain : A Journal Of Neurology* 137 (Pt 1):44-56 (PMID: 24253200) 118. Manole A, Houlden H. *Riboflavin Transporter Deficiency Neuropathy*. 2015 Jun 11. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews® [Internet]*. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK299312/>. 119. Kayman-Kurekci et al. (2014) *Neuromuscul. Disord.* 24 (7):624-33 (PMID: 24856141) 120. Ghaoui et al. (2015) *JAMA Neurol* 12 (12):1424-32 (PMID: 26436962) 121. Bögershausen et al. (2013) *Am. J. Hum. Genet.* 93 (1):181-90 (PMID: 23830518) 122. Knierim et al. (2016) *Am. J. Hum. Genet.* 98 (3):473-89 (PMID: 26924529) 123. Kimonis V, Donkervoort S, Watts G. *Inclusion Body Myopathy with Paget Disease of Bone and/or Frontotemporal Dementia*. 2007 May 25 [Updated 2011 Jul 28]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews® [Internet]*. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1476/>. 124. Zhou et al. (2012) *American Journal Of Human Genetics* 91 (1):5-14 (PMID: 22703880) 125. Gess et al. (2014) *Neurology* 83 (19):1726-32 (PMID: 25274842)